Mucopolysaccharidosis type VI (MPS VI)

Disease Overview

Mucopolysaccharidosis type VI (MPS VI) is a rare, progressive genetic disorder characterized by the body's inability to break down specific complex sugar molecules (glycosaminoglycans) due to a deficient enzyme. The condition leads to widespread cellular and organ damage, causing significant physical and developmental challenges.

Disease Category

Lysosomal Storage Disorder (LSD) Metabolic Disorder Genetic Disorder

Synonyms

Maroteaux-Lamy Syndrome
Arylsulfatase B Deficiency
MPS 6
Polydystrophic Dwarfism

Signs & Symptoms

Progressive symptoms include: Physical Characteristics: - Short stature - Coarse facial features - Skeletal deformities - Joint stiffness and contractures - Enlarged liver and spleen

Organ System Complications: - Cardiac valve abnormalities - Respiratory difficulties - Corneal clouding - Hearing loss - Recurrent ear infections - Hernias - Spinal cord compression

Causes

Genetic Basis: - Autosomal recessive inheritance - Mutations in the ARSB gene - Results in deficiency of arylsulfatase B enzyme - Leads to accumulation of dermatan sulfate in cells and tissues

Affected Populations

Prevalence: 1 in 250,000 to 1 in 600,000 births
Affects all ethnic groups equally
No gender predilection
Typically diagnosed in early childhood

Disorders with Similar Symptoms

Mucopolysaccharidosis type I (Hurler syndrome)
Mucopolysaccharidosis type II (Hunter syndrome)
Mucopolysaccharidosis type IV (Morquio syndrome)
Other lysosomal storage disorders

Diagnosis

Diagnostic Approach: - Comprehensive clinical evaluation - Urine glycosaminoglycan screening - Enzyme activity assay - Genetic mutation analysis - Imaging studies (X-rays, MRI) - Cardiac and respiratory function tests

Standard Therapies

Primary Treatments: - Enzyme Replacement Therapy (ERT) with galsulfase - Symptomatic management - Physical and occupational therapy - Orthopedic interventions - Respiratory support - Cardiac monitoring

Clinical Trials and Studies

Research Focus Areas: - Gene therapy - Enhanced enzyme replacement strategies - Small molecule therapies - Long-term treatment outcomes

References

Online Mendelian Inheritance in Man (OMIM)
National Institutes of Health (NIH)
Rare Disease Clinical Research Network
International scientific journals specializing in metabolic disorders

Programs & Resources

Support Organizations: - National MPS Society - Global Genes - National Organization for Rare Disorders (NORD) - International MPS Network - Genetic and Rare Diseases Information Center

Complete Report

Mucopolysaccharidosis type VI is a complex genetic disorder requiring multidisciplinary management. Early diagnosis, comprehensive care, and ongoing research are crucial for improving patient outcomes and quality of life.